Novel Opioid Receptor Agonists With Reduced Morphine-like Side Effects

Lianghan Zhu, Zhiying Cui, Qihua Zhu, Xiaoming Zha, Yungen Xu

Mini Rev Med Chem. 2018;18(19):1603-1610.

PMID: 30009707

Abstract:

Opioid analgesics, such as morphine, are widely employed in the treatment of moderate to severe pain. However, they are notorious for abuse liability and respiratory depression. Therefore circumventing the side effects, such as euphoria, addiction, respiratory depression and gastrointestinal adverse reactions, is of extensive importance. Recently, a large number of research results have revealed that such morphine-like side effects are not inevitable, and they focus on the novel approaches to disconnecting the analgesics from adverse effects. In this review, we mainly discuss the approaches including biasing the GPCRs over β-arrestin2 recruitment (TRV130, PZM21, HS665), the positive allosteric modulators of the MOR (BMS-986122) and multiple agonists of opioid receptors subtypes (SNC80, DPI-125). Besides these, we also introduce the key protein sites of MOR and β-arrestin2 recruitment briefly.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP313669884	BMS-986122		313669-88-4	Price